Business

Mindteck Reports Financial Results for the Quarter and Nine Months Ended December 31, 2024

Feb 06, 2025

BusinessWire India
Bengaluru (Karnataka) [India], February 6: Mindteck (India) Limited (BSE: 517344 and NSE: MINDTECK), the global engineering and technology solutions company with niche knowledge and expertise in the storage, medical device, semiconductor and analytical instrument industries, reported its unaudited financial results for the third quarter ended December 31, 2024.
The company's consolidated revenue for the quarter stood at Rs. 104.02 crore as against Rs. 108.23 crore for the previous quarter ended September 30, 2024, and Rs. 95.75 crore for the corresponding quarter ended December 31, 2023. Consolidated net profit for the quarter stood at Rs. 7.93 crore as against a profit of Rs. 7.57 crore for the previous quarter ended September 30, 2024, and Rs. 7.19 crore for the corresponding quarter ended December 31, 2023.
YTD revenue for the nine months ended December 31, 2024, stood at Rs. 320.40 crore as against Rs. 287.63 crore for the nine months ended December 31, 2023 - a growth of 11.4%. YTD profit for the nine months ended December 31, 2024 stood at Rs. 23.61 crore (before exceptional item) as against Rs. 20.83 crore for the nine months ended December 31, 2023 - a growth of 13.3%. The Basic EPS of the company stood at Rs. 6.90 per share for the nine months ended December 31, 2024, as against Rs. 6.70 per share for the nine months ended December 31, 2023.
The company's standalone revenue for the quarter stood at Rs. 35.87 crore as against Rs. 39.17 crore for the previous quarter ended September 30, 2024, and Rs. 34.67 crore for the corresponding quarter ended December 31, 2023. Standalone's net profit for the quarter stood at Rs. 3.29 crore as against a profit of Rs. 4.41 crore for the previous quarter ended September 30, 2024, and Rs. 4.42 crore for the corresponding quarter ended December 31, 2023.
YTD standalone revenue for the nine months ended December 31, 2024 stood at Rs. 116.48 crore as against Rs. 103.59 crore for the nine months ended December 31, 2023 - a growth of 12.4%. YTD profit for the nine months ended December 31, 2024 stood at Rs. 11.56 crore as against Rs. 12.53 crore for the nine months ended December 31, 2023. The Basic EPS of the company stood at Rs. 3.63 per share for the nine months ended December 31, 2024, as against Rs. 3.96 per share for the nine months ended December 31, 2023.
The Chairman of the Board, Mr. Yusuf Lanewala, commented on the results: "We are pleased to report another strong quarter, with solid performance and profitability. The IT industry continues to evolve rapidly, driven by cloud computing, AI, and cybersecurity advancements. Despite market challenges, our strategic focus keeps us ahead of the curve. We remain committed to innovation, operational excellence, and delivering long-term value to our stakeholders."
Adding to this, Anand Balakrishnan, the CEO, said, "The Company has delivered a strong performance for the quarter and successfully secured 10 new business deals. These results highlight the growing demand for our solutions and our ability to adapt in an evolving industry. As we look ahead, we remain committed to pushing boundaries, forging new opportunities, and delivering even greater value."
For more information, contact gnana.murthy@mindteck.com.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)

More news

Hexaware and Abluva Join Forces to Deliver Secure Agentic AI Solutions for the Life Sciences Industry

Mumbai (Maharashtra) [India]/ Iselin (New Jersey) [US], July 10: Hexaware Technologies, a global provider of IT services and solutions, today announced a strategic partnership with Abluva, an innovator in agentic AI security, to address security challenges posed by autonomous AI agents in the Life Sciences industry. This collaboration brings together Hexaware's deep domain expertise and Abluva's groundbreaking Secure Intelligence Plane to help organizations in the sector deploy generative AI (GenAI) safely and in compliance with industry regulations. As Life Sciences organizations increasingly adopt agentic AI to enhance research, clinical trials, patient data management, and commercial operations, the partnership ensures that AI agents operate in a secure, governed, and auditable environment--without hindering innovation. Delivering Governed and Secure Generative AI Agents for Life Sciences Innovation.

Jul 10, 2025